Authors
Gerald F. Watts
David R. Sullivan
David L. Hare
Karam M. Kostner
Ari E. Horton
Damon A. Bell
Tom Brett
Ronald J. Trent
Nicola K. Poplawski
Andrew C. Martin
Shubha Srinivasan
Robert N. Justo
Clara K. Chow
Jing Pang
Zanfina Ademi
Justin J. Ardill
Wendy Barnett
Timothy R. Bates
Lawrence J. Beilin
Warrick Bishop
J. Andrew Black
Alex Brown
John R. Burnett
Christina A. Bursill
Alison Colley
Peter M. Clifton
Elif I. Ekinci
Gemma A. Figtree
Brett H. Forge
Jacquie Garton-Smith
Dorothy F. Graham
Ian Hamilton-Craig
Christian R. Hamilton-Craig
Clare Heal
Charlotte M. Hespe
Amanda J. Hooper
Laurence G. Howes
Jodie Ingles
Edward D. Janus
Nadarajah Kangaharan
Anthony C. Keech
Andrew B. Kirke
Leonard Kritharides
Campbell V. Kyle
Paul Lacaze
Stephen C. H. Li
Stjepana Maticevic
Brendan M. McQuillan
Sam Mirzaee
Trevor A. Mori
Allison C. Morton
David M. Colquhoun
Joanna C. Moullin
Paul J. Nestel
Kristen J. Nowak
Richard C. O'Brien
Nicholas Pachter
Michael M. Page
Peter J. Psaltis
Jan Radford
Nicola J. Reid
Elizabeth N. Robertson
Jacqueline D. M. Ryan
Mitchell N. Sarkies
Carl J. Schultz
Russell S. Scott
Christopher Semsarian
Leon A. Simons
Catherine Spinks
Andrew M. Tonkin
Frank van Bockxmeer
Kathryn E. Waddell-Smith
Natalie C. Ward
Harvey D. White
Andrew M. Wilson
Ingrid Winship
Ann Marie Woodward
Stephen J. Nicholls
Peter Brett
Luke Elias
Wynand Malan
John Irvin
Kirsten Lambert, Edith Cowan UniversityFollow
Annette Pedrotti
FH Australasia Network Consensus Working Group
Document Type
Other
Publication Title
American Journal of Preventive Cardiology
Publisher
Elsevier
School
School of Education
RAS ID
35989
Funders
WAHTN Early Career Fellowship Australian Government's Medical Research Future Fund
Abstract
Introduction Familial hypercholesterolaemia (FH) is a common, heritable and preventable cause of premature coronary artery disease, with significant potential for positive impact on public health and healthcare savings. New clinical practice recommendations are presented in an abridged guidance to assist practitioners in enhancing the care of all patients with FH. Main recommendations Core recommendations are made on the detection, diagnosis, assessment and management of adults, children and adolescents with FH. There is a key role for general practitioners (GPs) working in collaboration with specialists with expertise in lipidology. Advice is given on genetic and cholesterol testing and risk notification of biological relatives undergoing cascade testing for FH; all healthcare professionals should develop skills in genomic medicine. Management is under-pinned by the precepts of risk stratification, adherence to healthy lifestyles, treatment of non-cholesterol risk factors, and appropriate use of low-density lipoprotein (LDL)-cholesterol lowering therapies, including statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Recommendations on service design are provided in the full guidance. Potential impact on care of FH These recommendations need to be utilised using judicious clinical judgement and shared decision making with patients and families. Models of care need to be adapted to both local and regional needs and resources. In Australia new government funded schemes for genetic testing and use of PCSK9 inhibitors, as well as the National Health Genomics Policy Framework, will enable adoption of these recommendations. A broad implementation science strategy is, however, required to ensure that the guidance translates into benefit for all families with FH.
DOI
10.1016/j.ajpc.2021.100151
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Comments
Watts, G. F., Sullivan, D. R., Hare, D. L., Kostner, K. M., Horton, A. E., Bell, D. A., ... Pedrotti, A. (2021). Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: An Australian perspective. American Journal of Preventive Cardiology, 6, article 100151. https://doi.org/10.1016/j.ajpc.2021.100151